Holen Sie sich die Stockscreener-App
73.25
4.11%
2.89
Handel nachbörslich:
73.00
-0.25
-0.34%
Schlusskurs vom Vortag:
$70.36
Offen:
$72.64
24-Stunden-Volumen:
1.36M
Relative Volume:
1.20
Marktkapitalisierung:
$2.05B
Einnahmen:
$62.60M
Nettoeinkommen (Verlust:
$-120.74M
KGV:
-16.07
EPS:
-4.5586
Netto-Cashflow:
$-190.35M
1W Leistung:
+3.61%
1M Leistung:
+2.69%
6M Leistung:
+50.47%
1J Leistung:
+8,883%
1-Tages-Spanne:
$70.00
$77.00
1-Wochen-Bereich:
$62.50
$77.00
52-Wochen-Spanne:
$0.432
$77.00
Nektar Therapeutics Stock (NKTR) Company Profile
Firmenname
Nektar Therapeutics
Sektor
Branche
Telefon
(415) 482-5300
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
73.25 | 1.97B | 62.60M | -120.74M | -190.35M | -4.5586 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-10 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | Eingeleitet | Citigroup | Buy |
| 2025-06-24 | Bestätigt | BTIG Research | Buy |
| 2025-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2025-04-11 | Hochstufung | Jefferies | Hold → Buy |
| 2025-03-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Eingeleitet | B. Riley Securities | Buy |
| 2024-12-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-09-30 | Fortgesetzt | BTIG Research | Buy |
| 2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-11-09 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-02-24 | Herabstufung | Jefferies | Hold → Underperform |
| 2022-08-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Fortgesetzt | Jefferies | Hold |
| 2022-04-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-15 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-03-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Neutral |
| 2021-06-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-02-22 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-09-14 | Eingeleitet | JP Morgan | Neutral |
| 2020-06-10 | Herabstufung | CFRA | Hold → Sell |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-22 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-30 | Hochstufung | Goldman | Sell → Neutral |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-08 | Herabstufung | Goldman | Buy → Sell |
| 2019-08-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-03-15 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-06-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Bestätigt | H.C. Wainwright | Buy |
| 2018-04-20 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-04-13 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-04-06 | Bestätigt | Mizuho | Buy |
| 2018-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Oppenheimer raises Nektar Therapeutics price target to $140 - Investing.com
Nektar Therapeutics (NKTR) PT Raised to $140 at Oppenheimer - StreetInsider
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
Nektar Q4 Earnings & Revenues Trump Estimates, Pipeline in Focus - TradingView
Nektar Therapeutics (NKTR) Surges After Beating Q4 Expectations - GuruFocus
Nektar Therapeutics stock hits 52-week high at 76.3 USD - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Q4 2025 Earnings Call Transcript - Insider Monkey
Nektar Therapeutics (NKTR) Reports Q4 and Full Year 2025 Financi - GuruFocus
NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - Sahm
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Highlights: Promising Phase 2B Results and ... By GuruFocus - Investing.com Canada
Nektar Therapeutics Reports 2025 Financial Results and Advances Rezpegaldesleukin to Phase 3 for Atopic Dermatitis - Minichart
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Highlights: Pro - GuruFocus
Nektar Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Nektar Therapeutics Q4 2025 shows cash boost and R&D expansion - Investing.com
Nektar (NKTR) Q4 2025 Earnings Call Transcript - AOL.com
Nektar Therapeutics (NKTR) Posts Fourth Quarter Loss, Exceeds Revenue Projections - Bitget
Nektar (NKTR) Reports Decrease in Q4 Revenue, Prepares for Phase 3 Trials - GuruFocus
Nektar: Q4 Earnings Snapshot - marketscreener.com
Nektar Therapeutics (NKTR) Misses Q4 EPS by 178c - StreetInsider
Nektar Therapeutics Q4 Swings to Loss, Revenue Declines - marketscreener.com
Earnings Flash (NKTR) Nektar Therapeutics Posts Q4 Loss Per Share $1.78, vs. FactSet Est of $2.47 Loss - marketscreener.com
Earnings Flash (NKTR) Nektar Therapeutics Reports Q4 Revenue $21.8M, vs. FactSet Est of $10.2M - marketscreener.com
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - PR Newswire
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - The AI Journal
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - Benzinga
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain OfficersNKTR - PR Newswire
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics ... - Bluefield Daily Telegraph
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein - GlobeNewswire
NKTR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Carroll County Mirror-Democrat
Nektar Therapeutics Q4 2025 earnings preview - MSN
Nektar Therapeutics Faces Class Action Lawsuit - Intellectia AI
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
NEKTAR THERAPEUTICS (NKTR) INVESTOR ALERT Investors With - GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure ... - Caledonian Record
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - ChartMill
FinancialContentPomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - FinancialContent
Important Notice to Long-Term Shareholders of Boston - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. Investors - GlobeNewswire
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Nektar Therapeutics Sued for Securities Law Violations - Benzinga
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - mydailyrecord.com
Will REZOLVE-AA Class Actions Over Trial Disclosures Change Nektar Therapeutics' (NKTR) REZPEG Narrative? - simplywall.st
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - PR Newswire
NKTR Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Against Nektar Therapeutics - Morningstar
Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their Rights - The AI Journal
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Nektar Therapeutics, (NKTR) - TMX Newsfile
303,200 Shares in Nektar Therapeutics $NKTR Acquired by Jefferies Financial Group Inc. - MarketBeat
NKTR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - TMX Newsfile
Nektar Therapeutics stock pops on $300M equity offering - MSN
Finanzdaten der Nektar Therapeutics-Aktie (NKTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nektar Therapeutics-Aktie (NKTR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ROBIN HOWARD W | President & CEO |
Feb 18 '26 |
Sale |
73.00 |
423 |
30,879 |
75,489 |
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):